Wolfe Research Initiates Coverage On Immunovant with Outperform Rating, Announces Price Target of $55
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Andy Chen initiates coverage on Immunovant (NASDAQ:IMVT) with an Outperform rating and a price target of $55.
February 15, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wolfe Research initiated coverage on Immunovant with an Outperform rating and a price target of $55.
The initiation of coverage by Wolfe Research with an Outperform rating and a high price target of $55 is likely to generate positive sentiment among investors, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100